Elizabeth A. M. O'FLynn

Elizabeth A. M. O'FLynn

Auto-generated profile, based on publicly available information

Elizabeth A. M. O'FLynn

St George’s University Hospitals NHS Foundation Trust, Radiology, London SW17 0QT, UK

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in Clinical Radiology
Verified
Journal Article
Closed access
EOE.A.M. O'FLynn
E.A.M. O'FLynn
AWA.R.M. Wilson
A.R.M. Wilson
MMM.J. Michell
M.J. Michell

23 February 2011 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
EOElizabeth Am O'FLynn
Elizabeth Am O'FLynn
NDNandita M deSouza
Nandita M deSouza
Functional magnetic resonance (MR) encompasses a spectrum of techniques that depict physiological and molecular processes before morphological changes are visible on conventional imaging. As understanding of the pathophysiological and biomolecular processes involved in breast malignancies evolves, newer functional MR techniques can be employed that define early predictive and surrogate biomarkers for monitoring response to chemotherapy. Neoadjuvant chemotherapy is increasingly used in women with primary breast malignancies to down-stage the tumour and enable successful breast conservation surgery. It also plays a role in the treatment of undetected micrometastases. Cardinal physiological features of tumours that occur as a result of interactions between cancer cells, stromal cells and secreted factors and cytokines and how they change with treatment provide the opportunity to detect changes in the tumour microenvironment prior to any morphological change. Through sequential imaging, tumour response can be assessed and non-responders can be identified early to enable alternative therapies to be considered. This review summarises the functional magnetic resonance biomarkers of response in patients with breast cancer that are currently available and under development. We describe the current state of each biomarker and explore their potential clinical uses and limitations in assessing treatment response. With the aid of selected interesting cases, biomarkers related to dynamic contrast-enhanced MRI, diffusion-weighted MRI, T2*/BOLD and MR spectroscopy are described and illustrated. The potential of newer approaches, such as MR elastography, are also reviewed.

26 February 2012 in European Radiology
Verified
Journal Article
Closed access
PDF file
EOElizabeth A. M. O’fLynn
Elizabeth A. M. O’fLynn
VMVeronica A. Morgan
Veronica A. Morgan
SGSharon L. Giles
Sharon L. Giles
NDNandita M. Desouza
Nandita M. Desouza

7 January 2003 in BJU International
Verified
Journal Article
Open access
PDF file
CBC.T. Brown
C.T. Brown
EOE. O'FLynn
E. O'FLynn
JMJ. Van Der Meulen
J. Van Der Meulen
SNS. Newman
S. Newman
AMA.R. Mundy
A.R. Mundy
MEM. Emberton
M. Emberton
OBJECTIVE: To explore the concerns and worries in men with uncomplicated lower urinary tract symptoms (LUTS, but no evidence of prostate cancer) relating to their symptoms. Patients and methods: There is no current prostate cancer screening programme in the UK. Evidence suggests that men with LUTS have the same risk of prostate cancer as aged‐matched asymptomatic men. However, most men with LUTS are ‘screened’ with a digital rectal examination (DRE) and prostate specific antigen (PSA) testing as part of routine assessment. Whether this screening offers any benefit to patients and whether national screening for prostate cancer and subsequent early treatment offer any long‐term survival or quality of life benefit is uncertain. Thus 30 men with uncomplicated LUTS were qualitatively interviewed to explore their concerns and worries about their symptoms. Interviews were transcribed verbatim and subjected to content analysis using validated techniques. RESULTS: Of the 30 men, 22 (73%) expressed a fear of prostate cancer at the time of their initial presentation. This fear was independent of race, social class and symptom severity; older men were less worried. Of the 22, 15 (68%) stated that after reassurance their symptoms were less bothersome and easier to cope with. CONCLUSIONS: These findings suggest there is a considerable gain in health by explicitly addressing the concerns of prostate cancer in men with uncomplicated LUTS. Informing these men of their true risk of prostate cancer (before or after a DRE and PSA estimate) may alleviate much of the bother associated with their symptoms. Despite no evidence of any greater risk of prostate cancer than in asymptomatic men, symptomatic men should continue to be screened after appropriate counselling.

1 August 2004 in European Urology
Verified
Journal Article
Closed access
CBChristian T Brown
Christian T Brown
JMJan Van Der Meulen
Jan Van Der Meulen
AMAnthony R Mundy
Anthony R Mundy
EOElizabeth O'Flynn
Elizabeth O'Flynn
MEMark Emberton
Mark Emberton

1 February 2009 in Clinical Radiology
Verified
Journal Article
Closed access
EOE.A.M. O'FLynn
E.A.M. O'FLynn
JMJ.C. Morel
J.C. Morel
JGJ. Gonzalez
J. Gonzalez
NDN. Dutt
N. Dutt
DED. Evans
D. Evans
MMM.J. Michell
M.J. Michell